

# Corporate Action Notice

December 16, 2015

## Name Change

### Circadian Technologies Limited - Name Change to - Opthea Limited

Please be advised that Circadian Technologies Limited announced a name change to Opthea Limited

The following identifiers have been assigned:

<b>Old OTC DR CUSIP:</b>	17254C100	<b>New OTC DR CUSIP:</b>	68386J109
<b>Old OTC DR ISIN:</b>	US17254C1009	<b>New OTC DR ISIN:</b>	US68386J1097

The effective date for the name change will be December 22, 2015.

DR holders need not take any action. Existing DR certificates will assume the new parameters and will not be subject to a mandatory exchange.

---

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

#### NEW YORK

Ravi Davis  
Richard J Maehr  
+ 1 212 815 2267  
adrdesk@bnymellon.com

#### LONDON

Jacek Jankowski  
Vice President  
+ 44 207 163 7427  
jacek.jankowski@bnymellon.com

#### SINGAPORE

Herston Powers  
Vice President  
+ 65 6432 0281  
herston.powers@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at <http://www.adrbnymellon.com/files/PB43451.pdf>.



BNY MELLON